Premium
Long‐acting injectables good option for schizophrenia patients
Author(s) -
Canady Valerie A.
Publication year - 2019
Publication title -
mental health weekly
Language(s) - English
Resource type - Journals
eISSN - 1556-7583
pISSN - 1058-1103
DOI - 10.1002/mhw.31861
Subject(s) - tolerability , schizophrenia (object oriented programming) , retention rate , baseline (sea) , medicine , psychiatry , adverse effect , business , political science , marketing , law
A six‐month study evaluating the efficacy, safety and tolerability of two‐long‐acting injectable medicines has provided a favorable overall retention rate, and both medications reveal significant improvements from baseline in schizophrenia symptoms, according to officials at Alkermes.